Address: 1 Sosnovaya St., Pokrov village, Podolsky district, Moscow region,142143,Russia
Tel: +7 (495) 984-2753/54
Established in 1996, Petrovax Pharm is a Russian company engaged in research, development, and manufacturing of innovative medicines and vaccines.
The Company’s strategy is built on development, manufacturing and introduction of innovative medicines developed on the basis of fundamental scientific research.
The Company’s portfolio includes only innovative medicines and vaccines, which are successfully commercialized by Petrovax Pharm in the Russia, CIS and EU.
Petrovax Pharm has three manufacturing sites located in Moscow and Moscow Region, which were built and operate in full compliance with the GMP EU and ISO:9001 international standards and equipped by modern high-tech equipment for production and post-production control. The new pharmaceutical manufacturing and storage complex in Pokrov (Moscow Region, Podolsk area) is one of the most state-of-the-art and hi-tech biopharmaceutical manufacturing facilities in Russia, focusing on production of vaccines and other immuno-biological products in individual syringe doses, and other pharmaceuticals in different medicinal forms.
Petrovax Pharm employs about 550 highly qualified specialists. The company conducts regular training and certification of its personnel, which helps boost the company’s competitiveness and strengthen its position in the market.
Being a member of the Association of Russian Pharmaceutical Manufacturers (ARPM) since 2008, Petrovax Pharm is aspiring to bring new business standards to the domestic pharmaceutical market with an objective of increasing confidence in the Russian economy.
The Company’s portfolio includes only innovative medicines and vaccines, which are successfully commercialized by Petrovax Pharm in the Russia, CIS and EU.
Petrovax has always been an innovative company, making it quite unique in Russia where the domestic industry is predominantly comprised of generics manufacturers. How would you describe the positioning of…
Valenta was established in 1997 as Otechestvennye Lekarstva, and today represents the consolidation of several facilities and business holding groups. Can you give our readers an overview of the company’s…
Since 2006, Russia has witnessed quite a dynamic few years, with sweeping legislative reforms like the Law on Circulation of Medicines and development strategies like Pharma 2020. What have been…
Baker & McKenzie differentiates itself from competitors by offering an industry-focused practice. Has this model continued to give this company a leading edge in Russia, and, overall, what is your…
There has been quite a bit of dynamism in the domestic pharmaceutical market since Focus Reports last look at the Russian market in 2006/2007. What have been the main changes…
Ferring is a specialty biopharmaceutical company that operates in four strategic therapeutic areas. Globally, many pharma companies have been diversifying their portfolio, and entering the OTC segment, generics segment, medical…
Lundbeck is a niche player exclusively focused on the treatment of CNS and mental health disorders. How developed do you find this niche to be in Russia? The size of…
Focus Reports first met with Materia Medica in 2006. At the time, the company was enjoying an extremely rapid pace of growth. Looking back over the last years, how has…
You took over this company in 2007, which was the pivotal year when a group of investors assumed control of Akrikhin and the main strategic investor was Polpharma. Since then,…
When our team interviewed Amit Makwana at Astellas’ European Headquarters in the UK, he noted that the Russian affiliate is experiencing a huge growth rate that is very difficult for…
The AEB works through a number of channels to promote the interests of European corporations with operations in Russia. It has a long history in this country, dating back to…
Novo Nordisk announced last year the development of an insulin plant in the Kaluga region not far from Moscow. What is the strategic significance of this plant, both for the…
Many expat managers have used Russia as a stepping-stone, but you have headed this business for an astounding 9 years. What is it about this country and about Reckitt Benckiser’s…
See our Cookie Privacy Policy Here
